WHO Prequalifies First Malaria Treatment for Newborns and Young Infants
The World Health Organization prequalified the first malaria treatment specifically formulated for newborns and infants weighing between 2 and 5 kilograms on April 24, 2026, addressing a key gap for the age group most vulnerable to severe complications from the disease. This adapted version of artemether-lumefantrine will integrate with existing vaccines and prevention tools to help lower infant mortality rates, according to the agency. The move, announced ahead of World Malaria Day, sets the stage for inclusion in national programs across high-burden areas in the coming months.
According to the WHO, the medication has been tailored to the developmental characteristics of infants starting at two months old, adjusting the therapeutic combination to suit their immune and metabolic profiles. The organization expects the formulation to improve outcomes against malaria parasites while minimizing risks associated with off-label use of treatments designed for older children. Officials highlighted its potential to enhance protection in regions where young children face the highest likelihood of acute anemia or cerebral malaria from infection. The prequalification process confirmed both safety and efficacy standards for this previously underserved patient group.
WHO figures show the African Region accounted for 95 percent of global malaria cases and deaths in 2024, totaling around 265 million cases and 579,000 deaths, with children under five years representing about 76 percent of fatalities in the region. A WHO assessment found that Nigeria, the Democratic Republic of the Congo and Niger together bore more than half of those African deaths. These statistics reflect the persistent challenge in high-transmission zones despite decades of international interventions, where infants remain at elevated risk due to limited prior treatment options.
The approval targets an estimated 30 million infants born each year in malaria-endemic parts of Africa and Southeast Asia, the WHO reported. Distribution will commence through national immunization and malaria control initiatives once countries complete their local regulatory reviews. The global health body noted that combining the new treatment with available vaccines should create a more comprehensive shield for the youngest patients in affected communities.
Progress toward global malaria reduction targets for 2030 has stalled in recent years amid rising drug resistance and funding pressures, according to WHO data. The infant-specific formulation adds to a suite of tools intended to accelerate declines in both incidence and mortality rates. Pharmaceutical partners collaborated on its development to ensure suitability for resource-limited health systems common in endemic countries.
Clinical studies that underpinned the prequalification demonstrated the treatment’s positive safety profile and effectiveness in the target age range, the Medicines for Malaria Venture reported. Healthcare providers in rollout countries will receive guidance on dosing and monitoring to maximize benefits. This advancement aligns with ongoing WHO efforts to close treatment gaps that have left newborns without dedicated antimalarial options until now.
